Group 1: Company Overview - Viking Therapeutics Inc is a healthcare service provider specializing in biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline includes VK2809, VK5211, and VK0214 products, with VK2809 and VK0214 being orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta, and VK5211 being an orally available, non-steroidal selective androgen receptor modulator [10]. Group 2: Options Trading Activity - Significant bullish positioning has been observed among high-rolling investors in Viking Therapeutics, with 13 options trades identified, indicating potential privileged information [1]. - The sentiment among major traders is evenly split, with 46% bullish and 46% bearish. Notably, there was one put option worth $35,245 and 12 call options totaling $547,650 [2]. - The predicted price range for Viking Therapeutics, based on volume and open interest analysis, is between $30.0 and $50.0 during the past quarter [3]. - The average open interest for options of Viking Therapeutics is 2,520.33, with total volume reaching 1,069.00, indicating active trading within the strike price corridor of $30.0 to $50.0 over the last 30 days [4]. Group 3: Options Trading Details - The largest options trades include a bullish call option with a strike price of $30.00, totaling $100.9K, and a neutral call option with a strike price of $37.50, totaling $100.0K. Other notable trades include a bearish call option at a strike price of $35.00 and another bullish call option at a strike price of $40.00 [9]. Group 4: Market Performance - The current trading volume for VKTX is 3,016,844, with the stock price down by 0.16%, reaching $38.49. Current RSI values indicate that the stock is neutral between overbought and oversold [15]. - A market expert has issued a consensus target price of $107.0 for Viking Therapeutics, with a Buy rating maintained by an analyst from Canaccord Genuity [12][13].

Core Insights - The article discusses the author's investment strategy and focus on Viking Therapeutics (VKTX), highlighting its potential as a long-term investment in the biotech sector [1]. Group 1: Investment Strategy - The author conducts an annual review of their portfolios, including top investment ideas from the Compounding Healthcare group [1]. - The focus is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [1]. Group 2: Company Overview - Viking Therapeutics is identified as one of the author's longest-standing investments, indicating confidence in its future performance [1]. - The author emphasizes a passion for biotech and life-saving therapies, stemming from years of experience in the medical field [1].

Core Insights - Viking Therapeutics (VKTX) shares have increased by 34% over the past three months, driven by positive investor sentiment regarding its obesity drug VK2735 [1][11]. Company Developments - Viking completed enrollment in the phase III VANQUISH-1 study, evaluating VK2735 in obese or overweight adults with at least one weight-related co-morbidity, surpassing the target with approximately 4,650 patients enrolled [2]. - The company also achieved rapid enrollment milestones earlier this year in the phase II VENTURE-Oral Dosing study, which evaluated an oral formulation of VK2735 [3]. - Currently, Viking is enrolling patients in the phase III VANQUISH-2 study, targeting nearly 1,100 obese or overweight adults with type II diabetes, with recruitment expected to complete by early 2026 [5]. Market Context - The obesity drug market is expanding, influenced by the success of competitors like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, indicating strong demand for VK2735 [4]. - The U.S. obesity market is projected to reach $100 billion by 2030, with major players optimizing production and developing new GLP-1-based candidates [7]. - Novo Nordisk and Eli Lilly are racing to introduce oral weight-loss pills, with Novo already seeking FDA approval for an oral version of Wegovy [8]. Competitive Landscape - Eli Lilly is investing in various obesity treatments, with several candidates in clinical development, including orforglipron and retatrutide, and plans to file for regulatory approval for orforglipron later this year [9]. Valuation and Performance - Viking Therapeutics shares are trading at a premium, with a price-to-book (P/B) ratio of 5.84 compared to the industry average of 3.60 [13]. - Despite the recent surge, VKTX shares have underperformed the industry year to date [12].

Core Insights - Viking Therapeutics is positioned to become a significant player in the weight loss market, competing against established companies like Novo Nordisk and Eli Lilly [1][2] Company Overview - Viking Therapeutics is a mid-cap biotech company that has faced challenges but has potential upside as it prepares to launch its first weight management medicine, VK2735 [2][8] - The company has a market capitalization of $4 billion and its stock has seen a decline since early last year, attributed to profit-taking by long-term shareholders [8] Product Development - VK2735, Viking's leading candidate, mimics the action of GLP-1 and GIP hormones and is currently in a pivotal phase 3 clinical trial after completing phase 2 studies [3][4] - The phase 3 trial began in June and is expected to conclude by August 2027, with potential FDA approval by late 2028 and market entry in early 2029 [4][5] Clinical Results - In a 13-week phase 2 study, VK2735 achieved a mean placebo-adjusted weight loss of 13.1%, showing competitive results compared to existing weight loss medications [6] - The oral formulation of VK2735 has also shown promising results, with an average weight loss of up to 12.2% in 13 weeks, despite high rates of study discontinuations due to adverse reactions [9][10] Future Pipeline - Viking has additional pipeline programs, including VK2809, targeting metabolic dysfunction-associated steatohepatitis (MASH), and another weight loss candidate expected to enter human clinical trials next year [11]

Core Insights - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [2] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City, including a fireside chat on December 2 [1] Company Overview - Viking Therapeutics specializes in first-in-class or best-in-class therapies for metabolic and endocrine disorders, with two programs currently in clinical trials [2] - The company's lead program, VK2735, is a dual agonist targeting GLP-1 and GIP receptors, showing positive safety and clinical benefit in Phase 1 and Phase 2 trials [2] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, achieving primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [2] - The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD), which demonstrated safety and significant reductions in VLCFAs in a Phase 1b trial [2]

Economic Impact of Tariffs - Trump's tariff policies are central to his economic strategy, with claims of strengthening the U.S. economy and curbing inflation, while the stock market has reportedly hit an "ALL-TIME HIGH for the 48th time in 9 months" [2][3] - A proposed $2,000 "tariff stimulus check" for middle-income Americans, funded by tariff revenues, raises skepticism among economists who argue that tariffs are typically paid by U.S. importers, leading to higher consumer prices [3][4] - Historical data shows that a significant increase in tariffs can negatively impact S&P 500 earnings, with Goldman Sachs estimating a 1-2% reduction in earnings per share for every five-percentage-point increase in tariff rates [4][6] Market Reactions and Volatility - Trump's announcements have led to significant market volatility, with major indices experiencing fluctuations despite achieving record highs, as seen on November 21, 2025, when the S&P 500 was down 2% despite a 0.92% rise in the US500 [5][12] - The VIX, a measure of market volatility, reached the mid-40s in April 2025, indicating extreme investor anxiety following tariff announcements [6][12] - The market's relationship with Trump's economic statements is characterized by unpredictability, with analysts noting that his pronouncements can trigger significant intraday market swings [11] Sector-Specific Impacts - Trump's directive for the Department of Justice to investigate the meatpacking industry over alleged price manipulation caused immediate stock price drops for major companies like JBS and Tyson Foods [8] - The pharmaceutical sector reacted sharply to Trump's price reduction promises for GLP-1 weight loss drugs, with stocks of companies like Novo Nordisk and Eli Lilly experiencing declines following his announcements [9][10] - Subsequent agreements to set drug prices at around $350 per month for Medicare and Medicaid recipients indicate a significant shift in the market landscape, although initial reactions were negative [10] Overall Market Sentiment - As of late November 2025, major indices showed a mix of gains and losses, reflecting the ongoing volatility and uncertainty in the market, with the S&P 500 down 2% despite a 1% increase on the same day [12] - The market continues to grapple with the implications of Trump's policies, oscillating between moments of optimism and underlying concerns about potential policy shifts [12]

Core Viewpoint - Viking Therapeutics, Inc. reported a wider-than-expected loss in Q3 2025, with shares showing a slight increase of about 1% since the last earnings report, outperforming the S&P 500 [1][3]. Financial Performance - The company reported a Q3 2025 loss of 81 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 70 cents, and a significant increase from a loss of 22 cents per share in the same quarter last year [3]. - Viking Therapeutics has not generated any revenues as it currently has no approved products in its portfolio [3]. - Research and development (R&D) expenses rose to $90 million, compared to $22.8 million in the year-ago period, driven by higher costs related to clinical studies, manufacturing, and increased employee-related expenses [4]. - General and administrative expenses decreased to $8.6 million, down nearly 38% year over year, primarily due to lower legal and patent service costs and stock-related compensation expenses [5]. - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $715 million, down from $808 million as of June 30, 2025 [5]. Market Reactions - Following the earnings release, there has been a downward trend in estimates revisions, with the consensus estimate shifting down by 19.23% [6]. - The stock currently has a poor Growth Score of F, a Momentum Score of D, and a Value Score of C, placing it in the middle 20% for the value investment strategy [7]. Outlook - Estimates for Viking Therapeutics have been trending downward, indicating a negative shift in market sentiment, with a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [8].

11/19/2025Viking Therapeutics stock fell Wednesday after the company said it... INVESTING RESOURCES 11/19/2025Viking Therapeutics stock fell Wednesday after the company said it overenrolled one of its final- phase studies for its weight-loss shot. MAGNIFICENT 7 : Why This Trader Expects More Pain Ahead Eli Lilly (LLY) became the first health care company to top $1 trillion in market capitalization on Friday, joining an exclusive club that includes big tech names like Nvidia (NVDA), Apple (AAPL) and Amazon.c ...

Company Highlights - Viking Therapeutics has completed enrollment of approximately 4,650 adults in the phase III VANQUISH-1 study for its obesity drug VK2735, surpassing its initial target of 4,500 patients [2][3][9] - The study evaluates the safety and efficacy of three subcutaneous dosing arms (7.5 mg, 12.5 mg, and 17.5 mg) against a placebo, with a primary endpoint of percent change in body weight after 78 weeks [2][9] - The company is also enrolling patients in the phase III VANQUISH-2 study, targeting nearly 1,100 obese or overweight adults with type II diabetes, with expected completion in Q1 2026 [5] Industry Context - The obesity market is projected to reach $100 billion in the United States by 2030, driven by the success of existing drugs from Eli Lilly and Novo Nordisk [11] - Both companies are actively developing new oral weight-loss medications, with Novo Nordisk seeking FDA approval for an oral version of Wegovy by the end of this year [12] - Pfizer has re-entered the obesity market by acquiring Metsera for around $10 billion, adding four novel clinical-stage programs to its portfolio, which could generate significant peak sales [15]

It’s been three months since my initial analysis on Viking Therapeutics, Inc. ( VKTX ), which coincided with the stock’s unprecedented one-day drop of over 40% — from around $42 to the mid-$20s. That sharp selloff was drivenI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked. I conduct my analyses in a way that allows me to use them my ...